Idorsia Pharmaceuticals Ltd.: Sleep Initiation and Maintenance Disorders trials

The registry lists 10 Sleep Initiation and Maintenance Disorders studies with Idorsia Pharmaceuticals Ltd. as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 2 4Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®RecruitingNCT06498128
• A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid NocturiaCompletedNCT05597020Phase 4Results posted
• Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to SleepCompletedNCT03679884Phase 3Results posted
• Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to SleepCompletedNCT03575104Phase 3Results posted
• Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia DisorderCompletedNCT03545191Phase 3Results posted
• Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia DisorderCompletedNCT02841709Phase 2Results posted
• Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia DisorderCompletedNCT02839200Phase 2Results posted
• Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)Active, not recruitingNCT06393504
• Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia DisorderCompletedNCT05423717Phase 2
• Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia DisorderCompletedNCT03056053Phase 2